JP2013521282A - ヒトプロガストリンペプチドに対する免疫原性組成物 - Google Patents
ヒトプロガストリンペプチドに対する免疫原性組成物 Download PDFInfo
- Publication number
- JP2013521282A JP2013521282A JP2012556067A JP2012556067A JP2013521282A JP 2013521282 A JP2013521282 A JP 2013521282A JP 2012556067 A JP2012556067 A JP 2012556067A JP 2012556067 A JP2012556067 A JP 2012556067A JP 2013521282 A JP2013521282 A JP 2013521282A
- Authority
- JP
- Japan
- Prior art keywords
- pro
- glu
- ser
- seq
- cys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
【選択図】 図1A
Description
pGlu-Gly-Pro-Trp-Ile-Glu-Glu-Glu-Glu-Glu-Ala-Ser-Ser-Pro-Pro-Pro-pro-Cys (配列番号3);
pGlu-Gly-Pro-Trp-Val-Glu-Glu-Glu-Glu-Glu-Ala-Ser-Ser-Pro-Pro-Pro-pro-Cys (配列番号4);
Cys-pro-Pro-Pro-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-Gly (配列番号5); および
Cys-pro-Pro-Pro-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-nPhe-Gly-Trp-Met-Asp-Phe-Gly (配列番号6)
からなる群より選択されるアミノ酸配列を有する。本発明に従えば、免疫原性担体を、特に、破傷風トキソイド、ジフテリアトキソイド、百日咳トキソイド、およびツベルクリン純粋タンパク質誘導体から選択することができる。
(2)pGlu-Gly-Pro-Trp-イソVal-Glu-Glu-Glu-Glu-Glu-Ala-Ser-Ser-Pro-Pro-Pro-pro-Cys (配列番号2)、「G-18」と命名、
(3)pGlu-Gly-Pro-Trp-イソVal-Glu-Glu-Glu-Glu-Glu-Ala-Ser-Ser-Pro-Pro-Pro-pro-Cys (配列番号3)、「G-18 LV」と命名(ヒトG17相同体)、
(4)pGlu-Gly-Pro-Trp-Ile- Glu-Glu-Glu-Glu-Glu-Ala-Ser-Ser-Pro-Pro-Pro-pro-Cys (配列番号4)、「G18 LI」と命名、
(5)Cys-pro-Pro-Pro-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-Gly (配列番号5)、「G-20」と命名、
(6)Cys-pro-Pro-Pro-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-nPhe-Gly-Trp-Met-Asp-Phe-Gly (配列番号6)、「G-20」と命名、
(7)Ser-Ser-Pro-Pro-Pro-pro-Cys (配列番号7)、7アミノ酸のペプチドであるセリル-プロリルスペーサー、
(8)Ser-Ser-pro-pro-pro-pro-Cys (配列番号8)、7アミノ酸のペプチドであるセリル-全部D-プロリルのスペーサー、
(9)Thr-Thr-Pro-Pro-Pro-pro-Cys (配列番号9)、7アミノ酸のペプチドであるトレオニル-プロリルスペーサー、
(10)Thr-Thr-pro-pro-pro-pro-Cys (配列番号10)、7アミノ酸のペプチドであるトレオニル-全部D-プロリルのスペーサー。
Claims (13)
- (A)(i)プロガストリンのアミノ酸配列またはプロガストリンのN末端および/もしくはC末端プロセッシングされた種、それに連結された(ii)7アミノ酸のスペーサーから構成される模倣ペプチドならびに(B)該模倣ペプチドにカップリングされた免疫原性担体を含むポリペプチド免疫原。
- 模倣ペプチドが、アミノ酸配列:Cys-pro-Pro-Pro-Pro-Ser-Ser-Gly-Trp-Met-Asp-nPhe-Gly-Arg-Arg-Ser-Ala-Glu-Asp-Glu-Asn(配列番号1)を有する、請求項1に記載のポリペプチド免疫原。
- 模倣ペプチドが、
pGlu-Gly-Pro-Trp-β-isoVal-Glu-Glu-Glu-Glu-Glu-Glu-Ala-Ser-Ser-Pro-Pro-Pro-pro-Cys (配列番号2);
pGlu-Gly-Pro-Trp-Ile-Glu-Glu-Glu-Glu-Glu-Ala-Ser-Ser-Pro-Pro-Pro-pro-Cys (配列番号3);
pGlu-Gly-Pro-Trp-Val-Glu-Glu-Glu-Glu-Glu-Ala-Ser-Ser-Pro-Pro-Pro-pro-Cys (配列番号4);
Cys-pro-Pro-Pro-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-Gly (配列番号5); および
Cys-pro-Pro-Pro-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-nPhe-Gly-Trp-Met-Asp-Phe-Gly (配列番号6)
からなる群より選択されるアミノ酸配列を有する、請求項1に記載のポリペプチド免疫原。 - 免疫原性担体が、破傷風トキソイド、ジフテリアトキソイド、百日咳トキソイド、およびツベルクリン純粋タンパク質誘導体からなる群より選択される、請求項1に記載のポリペプチド免疫原組成物。
- 免疫原性担体が破傷風トキソイドである、請求項4に記載のポリペプチド免疫原性組成物。
- 有効量の請求項1に記載のポリペプチド免疫原および該免疫原のための製薬上許容し得るビヒクルを含む免疫原性組成物。
- 製薬上許容し得る担体が、前記免疫原が存在する水相、および油相のエマルジョンを含む、請求項6に記載の免疫原性組成物。
- 油相がスクアレン、スクアラン、モノオレイン酸ソルビタン、ポリソルベート40およびポリソルベート80のうちの少なくとも1種を含む、請求項7に記載の免疫原性組成物。
- 油相が乳化剤を含む、請求項7に記載の免疫原性組成物。
- 油相または水相のいずれかが少なくとも1種のアジュバントを含有する、請求項7に記載の免疫原性組成物。
- アジュバントが、Nor-MDP、イミキモッド、環状ジグアニル酸、トレオニル-N-アセチル-ムラミル-L-アラニル-D-イソグルタミン、イソプリノシン、トレハロースジミコール酸、QS-21、α-ガラクトシルセラミド、およびα-グルコシルセラミドからなる群より選択される、請求項10に記載の免疫原性組成物。
- アジュバントが、Ergamisol、Cimetidine、Praziquantel、尿酸、マンナンおよびマンナンの誘導体、ならびにビタミンEからなる群より選択される、請求項10に記載の免疫原性組成物。
- Ser-Ser-Pro-Pro-Pro-pro-Cys (配列番号7);
Ser-Ser-pro-pro-pro-pro-Cys (配列番号8);
Thr-Thr-Pro-Pro-Pro-pro-Cys (配列番号9); および
Thr-Thr-pro-pro-pro-pro-Cys (配列番号10)
からなる群より選択されるスペーサーペプチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010116229.3 | 2010-03-03 | ||
CN2010101162293A CN101797382B (zh) | 2010-03-03 | 2010-03-03 | 抗人前胃液素多肽免疫组合物 |
PCT/US2011/000413 WO2011109106A2 (en) | 2010-03-03 | 2011-03-03 | Immunogenic compositions against human progastrin peptides |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013521282A true JP2013521282A (ja) | 2013-06-10 |
JP2013521282A5 JP2013521282A5 (ja) | 2014-04-17 |
JP5960064B2 JP5960064B2 (ja) | 2016-08-02 |
Family
ID=42593323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012556067A Expired - Fee Related JP5960064B2 (ja) | 2010-03-03 | 2011-03-03 | ヒトプロガストリンペプチドに対する免疫原性組成物 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP5960064B2 (ja) |
KR (2) | KR101957894B1 (ja) |
CN (1) | CN101797382B (ja) |
WO (1) | WO2011109106A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021167831A (ja) * | 2015-12-31 | 2021-10-21 | プロガストリン、エ、カンセル、エス、アー エル、エルProgastrine Et Cancers S.A R.L. | 胃癌の検出および治療のための組成物および方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111491660A (zh) * | 2017-08-22 | 2020-08-04 | 免疫洛克斯有限公司 | 用于治疗肺癌和其他癌症的肿瘤相关增殖肽和相关抗癌免疫原的组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5468494A (en) * | 1993-11-12 | 1995-11-21 | Aphton Corp. | Immunogenic compositions against human gastrin 17 |
US5866128A (en) * | 1989-01-24 | 1999-02-02 | Aphton Corporation | Method for the treatment and prevention of gastric and duodenal ulcer |
WO1999059628A2 (en) * | 1998-05-15 | 1999-11-25 | Aphton Corporation | Combination therapy for the treatment of tumors |
US20070248608A1 (en) * | 2004-09-22 | 2007-10-25 | Aphton Corporation | Monoclonal Antibodies to Progastrin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2005102A (en) * | 1931-05-21 | 1935-06-18 | Barrett Co | Distillation of tar |
US6258550B1 (en) * | 1993-04-23 | 2001-07-10 | Virginia Commonwealth University | Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site |
US6084066A (en) * | 1993-10-29 | 2000-07-04 | Virginia Commonwealth University | Polypetides that include conformation-constraining groups which flank a protein-protein interaction site |
PT889735E (pt) | 1996-02-08 | 2011-07-19 | Cancer Advances Inc | Métodos imunológicos para o tratamento do cancro gastrointestinal |
CN100558747C (zh) * | 2006-04-06 | 2009-11-11 | 海南天源康泽医药科技有限公司 | 以白喉毒素突变体crm197为载体的免疫原及其制备方法与应用 |
WO2008076454A1 (en) * | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
-
2010
- 2010-03-03 CN CN2010101162293A patent/CN101797382B/zh active Active
-
2011
- 2011-03-03 KR KR1020177036258A patent/KR101957894B1/ko active IP Right Grant
- 2011-03-03 KR KR1020127024509A patent/KR101847224B1/ko active IP Right Grant
- 2011-03-03 WO PCT/US2011/000413 patent/WO2011109106A2/en active Application Filing
- 2011-03-03 JP JP2012556067A patent/JP5960064B2/ja not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866128A (en) * | 1989-01-24 | 1999-02-02 | Aphton Corporation | Method for the treatment and prevention of gastric and duodenal ulcer |
US5468494A (en) * | 1993-11-12 | 1995-11-21 | Aphton Corp. | Immunogenic compositions against human gastrin 17 |
JPH09505056A (ja) * | 1993-11-12 | 1997-05-20 | アフトン・コーポレーション | ヒトガストリン17に対する改良された免疫原性組成物 |
WO1999059628A2 (en) * | 1998-05-15 | 1999-11-25 | Aphton Corporation | Combination therapy for the treatment of tumors |
US20070248608A1 (en) * | 2004-09-22 | 2007-10-25 | Aphton Corporation | Monoclonal Antibodies to Progastrin |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021167831A (ja) * | 2015-12-31 | 2021-10-21 | プロガストリン、エ、カンセル、エス、アー エル、エルProgastrine Et Cancers S.A R.L. | 胃癌の検出および治療のための組成物および方法 |
JP7478708B2 (ja) | 2015-12-31 | 2024-05-07 | プロガストリン、エ、カンセル、エス、アー エル、エル | 胃癌の検出および治療のための組成物および方法 |
Also Published As
Publication number | Publication date |
---|---|
JP5960064B2 (ja) | 2016-08-02 |
CN101797382B (zh) | 2013-11-20 |
KR20130075722A (ko) | 2013-07-05 |
KR101957894B1 (ko) | 2019-03-13 |
KR101847224B1 (ko) | 2018-04-10 |
CN101797382A (zh) | 2010-08-11 |
WO2011109106A3 (en) | 2012-01-19 |
KR20170142214A (ko) | 2017-12-27 |
WO2011109106A2 (en) | 2011-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5023077A (en) | Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease | |
US5607676A (en) | Immunogenic compositions against gastrin peptides | |
KR101240547B1 (ko) | T-헬퍼 및 b-세포 에피토프를 포함하는 신규한 면역원성리포펩타이드 | |
JPH09503742A (ja) | ワクチン用免疫原性lhrhペプチド構築体および合成普遍免疫刺激器 | |
US20060276400A1 (en) | Modulation of cholesteryl ester transfer protein (CETP) activity | |
US6861510B1 (en) | Immunogenic compositions against gastrin peptides | |
JP5960064B2 (ja) | ヒトプロガストリンペプチドに対する免疫原性組成物 | |
US11911451B2 (en) | Composition of tumor-associated proliferative peptides and related anti-cancer immunogen for the treatment of lung cancers and other cancers | |
US10660949B2 (en) | Vaccination using plant virus particles linked to HER2 antigens | |
US9550806B2 (en) | Immunogenic compositions against human progastrin peptides | |
JP2003532740A (ja) | キメラペプチド免疫原 | |
CA2233882A1 (en) | Pseudomonas exotoxin as immunogenic carrier in synthetic conjugate vaccines | |
JP2002518033A (ja) | 農場動物の成長促進のための合成ソマトスタチン免疫原 | |
US20040202673A1 (en) | Constructs of branched synthetic peptide immunogens with artificial T helper cell epitopes coupled to B cell epitopes | |
JP2001505763A (ja) | Hiv p―17ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法 | |
KR102301961B1 (ko) | 아밀로이드 접합체 및 그의 용도 및 방법 | |
WO2001043769A2 (en) | Antigen delivery | |
EP3990010A1 (en) | Stabilized chimeric synthetic proteins and therapeutic uses thereof | |
WO2013088141A1 (en) | Polypeptide comprising the sequence egpwleeeeeayg linked to an immunogenic carrier | |
DK173981B1 (da) | Farmaceutisk antigenetisk formulering | |
MXPA00011752A (en) | Synthetic somatostatin immunogen for growth promotion in farm animals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140228 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150414 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150708 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151013 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160421 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160524 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160622 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5960064 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |